Search research articles
Contact Us
Filters
Showing results (501-510 of 549) with videos related to
Page
of 55
Sort By:
Journal of Cellular Physiology
|
December 20, 2018
Clusterin enhances AKT2-mediated motility of normal and cancer prostate cells through a PTEN and PHLPP1 circuit
Jessika Bertacchini, Laura Mediani, Francesca Beretti, et al.
Oncotarget
|
December 29, 2012
A combination of temsirolimus, an allosteric mTOR inhibitor, with clofarabine as a new therapeutic option for patients with acute myeloid leukemia
Francesca Chiarini, Annalisa Lonetti, Gabriella Teti, et al.
Advances in Biological Regulation
|
June 5, 2018
Roles of p53, NF-κB and the androgen receptor in controlling NGAL expression in prostate cancer cell lines
William H Chappell, Saverio Candido, Stephen L Abrams, et al.
Leukemia
|
March 5, 2010
Erucylphosphohomocholine, the first intravenously applicable alkylphosphocholine, is cytotoxic to acute myelogenous leukemia cells through JNK- and PP2A-dependent mechanisms
A M Martelli, V Papa, P L Tazzari, et al.
Leukemia
|
October 5, 2011
AMP-dependent kinase/mammalian target of rapamycin complex 1 signaling in T-cell acute lymphoblastic leukemia: therapeutic implications
C Grimaldi, F Chiarini, G Tabellini, et al.
International Journal of Leprosy and Other Mycobacterial Diseases : Official Organ of the International Leprosy Association
|
March 6, 2002
Distinct histopathological patterns in single lesion leprosy patients treated with single dose therapy (ROM) in the Brazilian Multicentric Study
M B Costa, P F Cavalcanti Neto, C M Martelli, et al.
Expert Opinion on Emerging Drugs
|
February 16, 2010
Emerging MEK inhibitors
James A McCubrey, Linda S Steelman, Steven L Abrams, et al.
Expert Opinion on Emerging Drugs
|
September 1, 2009
Emerging Raf inhibitors
James A McCubrey, Linda S Steelman, Steven L Abrams, et al.
Leukemia
|
November 21, 2013
Cytotoxic activity of the casein kinase 2 inhibitor CX-4945 against T-cell acute lymphoblastic leukemia: targeting the unfolded protein response signaling
F Buontempo, E Orsini, L R Martins, et al.
Advances in Biological Regulation
|
October 10, 2017
Effects of berberine, curcumin, resveratrol alone and in combination with chemotherapeutic drugs and signal transduction inhibitors on cancer cells-Power of nutraceuticals
James A McCubrey, Stephen L Abrams, Kvin Lertpiriyapong, et al.
Page
of 55
Search research articles
Search
Showing results (501-510 of 549) with videos related to
Sort By:
Page
of 55
Journal of Cellular Physiology
|
December 20, 2018
Clusterin enhances AKT2-mediated motility of normal and cancer prostate cells through a PTEN and PHLPP1 circuit
Jessika Bertacchini, Laura Mediani, Francesca Beretti, et al.
Oncotarget
|
December 29, 2012
A combination of temsirolimus, an allosteric mTOR inhibitor, with clofarabine as a new therapeutic option for patients with acute myeloid leukemia
Francesca Chiarini, Annalisa Lonetti, Gabriella Teti, et al.
Advances in Biological Regulation
|
June 5, 2018
Roles of p53, NF-κB and the androgen receptor in controlling NGAL expression in prostate cancer cell lines
William H Chappell, Saverio Candido, Stephen L Abrams, et al.
Leukemia
|
March 5, 2010
Erucylphosphohomocholine, the first intravenously applicable alkylphosphocholine, is cytotoxic to acute myelogenous leukemia cells through JNK- and PP2A-dependent mechanisms
A M Martelli, V Papa, P L Tazzari, et al.
Leukemia
|
October 5, 2011
AMP-dependent kinase/mammalian target of rapamycin complex 1 signaling in T-cell acute lymphoblastic leukemia: therapeutic implications
C Grimaldi, F Chiarini, G Tabellini, et al.
International Journal of Leprosy and Other Mycobacterial Diseases : Official Organ of the International Leprosy Association
|
March 6, 2002
Distinct histopathological patterns in single lesion leprosy patients treated with single dose therapy (ROM) in the Brazilian Multicentric Study
M B Costa, P F Cavalcanti Neto, C M Martelli, et al.
Expert Opinion on Emerging Drugs
|
February 16, 2010
Emerging MEK inhibitors
James A McCubrey, Linda S Steelman, Steven L Abrams, et al.
Expert Opinion on Emerging Drugs
|
September 1, 2009
Emerging Raf inhibitors
James A McCubrey, Linda S Steelman, Steven L Abrams, et al.
Leukemia
|
November 21, 2013
Cytotoxic activity of the casein kinase 2 inhibitor CX-4945 against T-cell acute lymphoblastic leukemia: targeting the unfolded protein response signaling
F Buontempo, E Orsini, L R Martins, et al.
Advances in Biological Regulation
|
October 10, 2017
Effects of berberine, curcumin, resveratrol alone and in combination with chemotherapeutic drugs and signal transduction inhibitors on cancer cells-Power of nutraceuticals
James A McCubrey, Stephen L Abrams, Kvin Lertpiriyapong, et al.
Page
of 55